WCN24-935 NELL-1 Membranous Nephropathy during treatment of Rheumatoid Arthritis with Adalimumab

WCN24-935 NELL-1 Membranous Nephropathy during treatment of Rheumatoid Arthritis with Adalimumab

Saved in:

Bibliographic Details
Main Author:	Joselyn Reyes Bahamonde
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924003942
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adalimumab in the treatment of early rheumatoid arthritis
by: Y A Sigidin, et al.
Published: (2008-04-01)

PROSPECT IN TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS WITH ADALIMUMAB
by: E.I. Alexeeva, et al.
Published: (2008-12-01)

ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
by: E.I. Alexeeva, et al.
Published: (2009-05-01)

WCN25-4468 NELL-1 POSITIVE MEMBRANOUS NEPHROPATHY: FAIR IS NOT ALWAYS FAIR!
by: AMIT PASARI, et al.
Published: (2025-02-01)

WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
by: Hiddo J.L. Heerspink, et al.
Published: (2024-04-01)

Adalimumab in the treatment of rheumatoid arthritis (review of the 2007 EULAR Congress materials)
by: Z. S. Alekberova
Published: (2016-05-01)

Efficacy and tolerability of adalimumab (humira) in patients with active rheumatoid arthritis
by: I G Salikhov, et al.
Published: (2010-12-01)

Digital Vasculitis in a Patient with Rheumatoid Arthritis Responded Well to Adalimumab
by: Senol Kobak, et al.
Published: (2014-01-01)

ADALIMUMAB DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING SUSTAINED REMISSION
by: N. V. Demidova, et al.
Published: (2018-07-01)

Lethality of patients with rheumatoid arthritis depending on adalimumab administration: imitation modeling
by: D V Goryachev, et al.
Published: (2009-10-01)

Adalimumab in treatment of psoriatic arthritis
by: V. V. Badokin
Published: (2008-08-01)

CHANGES OF CYTOKINE LEVELS DURING THERAPY WITH METHOTREXATE AND ADALIMUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (REMARCA STUDY)
by: A. S. Avdeeva, et al.
Published: (2014-06-01)

National Rheumatology Summit. Place of adalimumab in current pharmacotherapy strategy for rheumatoid arthritis
by: Article Editorial
Published: (2015-09-01)

Immunological effects of adalimumab in rheumatoid arthritis: Results of a Russian national study
by: Dmitri Evgenyevich Karateev, et al.
Published: (2013-06-01)

WCN24-2238 EXOSTOSIN 1- AND 2- POSITIVE MEMBRANOUS NEPHROPATHY IN CHINESE PATIENTS
by: Hong Cheng, et al.
Published: (2024-04-01)

Infiltrations of plasma cells in synovium predict inadequate response to Adalimumab in Rheumatoid Arthritis patients
by: Jian Bin Li, et al.
Published: (2024-10-01)

WCN24-2320 ANALYSIS OF CLINICOPATHOLOGICAL CHARACTERISTICS OF MEMBRANOUS NEPHROPATHY WITH CONCOMITANT MALIGNANCY AND LITERATURE REVIEW
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-2274 CLINICOPATHOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF IDIOPATHIC MEMBRANOUS NEPHROPATHY WITH DUAL ANTIGEN POSITIVITY
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN25-726 NELL1-ASSOCIATED MEMBRANOUS NEPHROPATHY: A DETAILED CASE SERIES WITH CLINICAL, PATHOLOGICAL, AND IMMUNOLOGICAL INSIGHTS
by: ASIFSADIQ WANI, et al.
Published: (2025-02-01)

WCN24-1086 THE EFFICIENCY AND SAFETY OF OBINUTUZUMAB IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY-A RETROSPECTIVE STUDY FROM CHINA
by: Chen Duqun, et al.
Published: (2024-04-01)

ADALIMUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013-12-01)

Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
by: Yasameen Abbas, et al.
Published: (2024-12-01)

WCN24-2057 RELAPSE RISK IN PATIENTS WITH MEMBRANOUS NEPHROPATHY AFTER INACTIVATED COVID-19 VACCINATION
by: Hanzhen Zhang, et al.
Published: (2024-04-01)

Exploring the comorbidity mechanisms of ITGB2 in rheumatoid arthritis and membranous nephropathy through integrated bioinformatics analysis
by: Wenlong Cao, et al.
Published: (2025-12-01)

WCN24-861 SUBCLINICAL RHABDOMYOLYSIS IN MESOAMERICAN NEPHROPATHY
by: Magdalena Madero, et al.
Published: (2024-04-01)

Characteristics and Outcomes of NELL1 Membranous Nephropathy in Lipoic Acid Users and Nonusers
by: Rupali S. Avasare, et al.
Published: (2024-05-01)

EFFICACY OF ADALIMUMAB IN EARLY RHEUMATOID ARTHRITIS IN RELATION TO ITS SERUM LEVEL AND THE PRESENCE OF ANTI-DRUG ANTIBODY
by: A. S. Avdeeva, et al.
Published: (2014-12-01)

Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis
by: Federica Rivolta, et al.
Published: (2023-03-01)

WCN25-336 A CAPTIVATING CASE OF NEURAL EPIDERMAL GROWTH FACTOR-LIKE 1 PROTEIN (NELL-1) ASSOCIATED MEMBRANOUS NEPHROPATHY
by: Satyanand Sathi, et al.
Published: (2025-02-01)

WCN25-4226 DYNAMIC INSIGHTS INTO THERAPEUTIC STRATEGIES AND LONGITUDINAL OUTCOMES: A RETROSPECTIVE ANALYSIS OF NELL1 POSITIVE MEMBRANOUS NEPHROPATHY COHORT
by: GURJOT SINGH, et al.
Published: (2025-02-01)

THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
by: Elena Yurievna Loginova, et al.
Published: (2010-06-01)

WCN24-2290 A novel approach to induce early remission in high-risk primary membranous nephropathy
by: Vladimir Dobronravov, et al.
Published: (2024-04-01)

Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trials
by: Vibeke Strand
Published: (2025-06-01)

Forensic Facial Approximation of the Skull Attributed to Wenceslas of Bohemia (ca. 907–935)
by: Cicero Moraes, et al.
Published: (2025-06-01)

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
by: Gerd R Burmester, et al.
Published: (2019-10-01)

Comparative effectiveness and safety of tofacitinib vs. adalimumab in patients with rheumatoid arthritis: A systematic review and meta-analysis
by: Chunyan Zhu, et al.
Published: (2025-06-01)

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease
by: Roy Fleischmann, et al.
Published: (2025-06-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

SYNOVIAL MEMBRANE CHANGES IN PATIENTS WITH RHEUMATOID ARTHRITIS REVEALED DURING ARTHROSCOPY
by: E. B. Komarova
Published: (2017-07-01)

The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients
by: Mateusz Makuch, et al.
Published: (2025-07-01)